This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emergent BioSolutions, Inc.
Drug Names(s): rhGH, recombinant human growth hormone, somatropin [rDNA origin]
Description: Accretropin is a recombinant human growth hormone, identical in sequence to natural human growth hormone. Natural human growth hormone is a protein produced by the pituitary gland that acts on the long bones of the body until the onset of puberty and promotes growth to normal stature. A deficiency of this hormone during childhood results in abnormally small stature.
Deal Structure: Accretropin was developed under a research and development agreement with the Apotex Group, Cangene's majority shareholder, and Apotex retains marketing rights for the product. Apotex will receive royalties and a profit share (in other agreements with Apotex, the royalty was 12% and the subsequent profits split, but details on the agreement for Accretropin have not been released).
In October 2003, Cangene announced that it had entered into an exclusive marketing and distribution agreement with BioGeneriX, a subsidiary of generic drug manufacturer Ratiopharm, for Cangene's recombinant human growth hormone. Under the agreement, BioGeneriX will be the sole distributor of the product in Europe. Cangene and BioGeneriX will pursue regulatory approval from the European Medicines Agency and any other authority necessary for sales in the region and will share in the costs and profits throughout the life of the agreement.
In April 2009, Cangene reported that it has signed a new agreement...See full deal structure in Biomedtracker
Partners: Teva Pharmaceutical Industries Ltd.
Additional information available to subscribers only: